125
Participants
Start Date
May 31, 2011
Primary Completion Date
December 31, 2013
Study Completion Date
December 31, 2013
nepafenac 0.1% drops
One drop three times per day for one year
Nepafenac Vehicle
Placebo
Eye Care for the Adirondacks, Plattsburgh
Retina-Vitreous Surgeons of Central New York, PC, Syracuse
Elman Retina Group, P.A., Baltimore
Charlotte Eye Ear Nose and Throat Assoc, PA, Charlotte
Southeast Retina Center, P.C., Augusta
Central Florida Retina Institute, Lakeland
Retina Consultants of Southwest Florida, Fort Myers
Southeastern Retina Associates, PC, Kingsport
Southeastern Retina Associates, P.C., Knoxville
Paducah Retinal Center, Paducah
Retina Associates of Cleveland, Inc., Beachwood
Raj K. Maturi, M.D., P.C., Indianapolis
American Eye Institute, New Albany
Henry Ford Health System, Dept of Ophthalmology and Eye Care Services, Detroit
Vitreo-Retinal Associates, Grand Rapids
Wolfe Eye Clinic, West Des Moines
Medical College of Wisconsin, Milwaukee
University of Minnesota, Minneapolis
Retinal Consultants of San Antonio, San Antonio
Texas Retina Associates, Lubbock
Retinal Consultants of Southern California Medical Group, Inc., Westlake Village
Southern California Desert Retina Consultants, MC, Palm Springs
Loma Linda University Health Care, Dept. of Ophthalmology, Loma Linda
California Retina Consultants, Santa Barbara
Bay Area Retina Associates, Walnut Creek
Retina Associates of Hawaii, Inc., Honolulu
Retina Northwest, PC, Portland
University of Washington Medical Center, Seattle
Retina and Vitreous Associates of Kentucky, Lexington
Joslin Diabetes Center, Boston
Eyesight Ophthalmic Services, PA, Portsmouth
Family Eye Group, Lancaster
Lead Sponsor
National Eye Institute (NEI)
NIH
Jaeb Center for Health Research
OTHER